Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study.

Niklas Worm Andersson Emilia Myrup Thiesson Jørgen Vinsløv Hansen Anders Hviid

Published in: BMJ (Clinical research ed.) (2023)

The use of bivalent mRNA vaccines as a fourth vaccine dose against covid-19 was not associated with an increased risk of 27 different adverse events in adults aged ≥50 years.

Keyphrases

coronavirus disease
sars cov
binding protein
cross sectional